Rapid development of sensitive, high-throughput, quantitative and highly selective mass spectrometric targeted immunoassays for clinically important proteins in human plasma and serum - Wikidata - wikimedia - TriplyDB

Rapid development of sensitive, high-throughput, quantitative and highly selective mass spectrometric targeted immunoassays for clinically important proteins in human plasma and serum

Rapid development of sensitive, high-throughput, quantitative and highly selective mass spectrometric targeted immunoassays for clinically important proteins in human plasma and serum

http://www.wikidata.org/entity/Q37187946

about

Applications of targeted proteomics in systems biology and translational medicine Advances in targeted proteomics and applications to biomedical research Mass spectrometric immunoassay and MRM as targeted MS-based quantitative approaches in biomarker development: potential applications to cardiovascular disease and diabetes Mass spectrometry assays of plasma biomarkers to predict radiographic progression of knee osteoarthritis.Quantitative mass spectrometric immunoassay for the chemokine RANTES and its variants.Integrating omics technologies to study pulmonary physiology and pathology at the systems level.Monolith immuno-affinity enrichment liquid chromatography tandem mass spectrometry for quantitative protein analysis of recombinant bovine somatotropin in serum.Contributions of immunoaffinity chromatography to deep proteome profiling of human biofluids Personalized Proteomics: The Future of Precision Medicine.Mass Spectrometric Immunoassays in Characterization of Clinically Significant Proteoforms.The role of quantitative mass spectrometry in the discovery of pancreatic cancer biomarkers for translational science.Sensitive glucagon quantification by immunochemical and LC-MS/MS methods.Current trends in mass spectrometry of peptides and proteins: Application to veterinary and sports-doping control.MRM for the verification of cancer biomarker proteins: recent applications to human plasma and serum.Mass spectrometry based biomarker discovery, verification, and validation--quality assurance and control of protein biomarker assays.The role of apolipoprotein E in neurodegeneration and cardiovascular disease.Applications of low-flow LC-SRM for the analysis of large molecules in pharmaceutical R&D.Liquid chromatography tandem mass spectrometry in the clinical laboratory.Sample preparation strategies for targeted proteomics via proteotypic peptides in human blood using liquid chromatography tandem mass spectrometry.Important options available--from start to finish--for translating proteomics results to clinical chemistry.Amyloid-β as a biomarker for Alzheimer's disease: quantification methods in body fluids.Clinical applications of MS-based protein quantification.Qualification and Verification of Protein Biomarker Candidates.Clinical translation of MS-based, quantitative plasma proteomics: status, challenges, requirements, and potential.Proteomic signatures of serum albumin-bound proteins from stroke patients with and without endovascular closure of PFO are significantly different and suggest a novel mechanism for cholesterol efflux Total and isoform-specific quantitative assessment of circulating fibulin-1 using selected reaction monitoring MS and time-resolved immunofluorometry.Quantification of seven apolipoproteins in human plasma by proteotypic peptides using fast LC-MS/MS.Multi-stage tandem mass spectrometric analysis of novel β-cyclodextrin-substituted and novel bis-pyridinium gemini surfactants designed as nanomedical drug delivery agents.An evaluation of an aptamer for use as an affinity reagent with MS: PCSK9 as an example protein.Quantification by nano liquid chromatography parallel reaction monitoring mass spectrometry of human apolipoprotein A-I, apolipoprotein B, and hemoglobin A1c in dried blood spots.Delivery of minimally dispersed liquid interfaces for sequential surface chemistry.Development of a mass spectrometry immunoassay for unambiguous detection of egg allergen traces in wines.Evolution of proteomic biomarker for chronic liver disease: Promise into reality.Parathyroid Hormone (PTH) Assays and Applications to Bone Disease: Overview on Methodology Parathyroid Hormone (PTH) Assays and Applications to Bone Disease: Overview on Methodology

P2860

Q26852271-F8E5DA60-B473-4327-8BB3-F7160424C4E1 Q28066912-098A0261-C4C1-43ED-8BE1-3E5F1FDC6C2B Q33643266-3D454945-0C28-4DED-BB2F-7D7685E87AD3 Q34392988-03F5C658-E792-4186-AB70-508CA15515B8 Q35166976-01B71F53-64A2-464F-8795-5C8636226D06 Q35413415-2361C07C-358D-488A-8E91-6C8190A97C0A Q35881938-76A54D6E-2DFD-46E8-B8DD-ED46C468FCE1 Q36889137-9BD1107B-67DD-472F-A1AB-8344567026BD Q37426540-873F56D6-77A0-4EDF-B64A-CBA82C12C4FE Q37566426-AB5FDAD3-9C04-496D-BE22-44D0BFFB649D Q37720601-A4739C5D-7399-4FCA-AF7E-A43864997067 Q38167833-9D25E96E-814A-471F-95CB-94F143C02E06 Q38174541-B55076D9-3C22-4A3C-A7E6-F436559B66C5 Q38183147-E5877C1D-BAF7-4266-A066-679E3AA25AF5 Q38203040-CA2D761D-8BD3-4502-BE25-53DE21D6ADB4 Q38206263-C840BBDF-F2F3-41C3-872A-A34B385F53A1 Q38243346-DD5662CD-4058-48DB-AE98-96D84FF803CE Q38260022-2EEA2B58-ED6F-4261-B54D-A7999B6E0F3F Q38270732-6D41570C-D99D-4A89-87E1-1A51E65BDDDD Q38282797-F2B99ACB-89BC-4013-8722-14FAB735508A Q38543843-FA602C47-CA38-4C59-A233-A1FF441931E5 Q38802991-5F891D02-E29D-4E98-AFFA-D7AB15D854F2 Q39099858-C93F91D3-9D3E-4402-AA4E-A0220C9548D7 Q39657160-CB5202AE-EC86-4C47-BB04-8A733F5F8523 Q41440445-E4149265-93BB-4D86-A93B-41CAA8210B99 Q44801298-228DD815-7062-4301-AC76-73BB1CA78007 Q45059705-96D325AA-DE57-40F2-A774-E988EF501825 Q46927013-A6A6B141-6A73-4B7E-8874-9EC8475E6B63 Q50786533-90913D51-C6DA-426F-9CFA-2CF4C06C9CEE Q51174001-28F0FC0C-20A8-4872-98A0-D40B0100F68B Q51275791-1FCB4203-627B-4706-A35F-B790D55128A9 Q51280239-09E96558-6C3C-4C9A-811C-E9E7139CA416 Q55091571-5C91D0DD-9175-448E-B9DD-B9D31819D993 Q58634097-F48A8F95-3811-4C40-935B-F9969991EB0E Q58634182-2B5B7C77-6B71-42EB-B733-0CAFABB6CF4A

P2860

Rapid development of sensitive, high-throughput, quantitative and highly selective mass spectrometric targeted immunoassays for clinically important proteins in human plasma and serum

http://www.wikidata.org/entity/Q37187946

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 08 January 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Rapid development of sensitive ...... eins in human plasma and serum

@en

Rapid development of sensitive ...... ins in human plasma and serum.

@nl

type

label

Rapid development of sensitive ...... eins in human plasma and serum

@en

Rapid development of sensitive ...... ins in human plasma and serum.

@nl

prefLabel

Rapid development of sensitive ...... eins in human plasma and serum

@en

Rapid development of sensitive ...... ins in human plasma and serum.

@nl

P1433

Q37187946-CC68AEB8-7F63-4476-A683-82B143A8AE32

P1476

Q37187946-B7474F1F-D59B-4DCF-AE45-964ED74C5E3E

P2093

Q37187946-04D1EC92-6384-4976-B8A8-2BAAC1ED8511

Q37187946-16F2A29D-A21F-4156-9BD1-33A1F7838234

Q37187946-1D1D1B6B-DD06-4699-9571-CBFF840F8D53

Q37187946-327E75B3-5DAB-4EF7-BC44-DB256B7F9BB0

Q37187946-5709CA12-A9E8-4C45-B725-4B6909BAB2F8

Q37187946-5E9B4907-5EB2-445A-AA39-1FA3ED33C0CD

Q37187946-69221CFB-4719-436A-96A1-6AB22DB303EC

Q37187946-7B949B1F-6401-4420-9EFF-252B00207D91

Q37187946-9775A2C4-92A6-4CE2-B528-49B867AB37DA

Q37187946-A2CDBF06-7C6A-4432-8D06-EA6805E1919D

P2860

Q37187946-010F9DFA-C5DA-4459-B47B-2DD23DE62093

Q37187946-01CC7443-4F88-464E-B1F5-5F43BB0E36E5

Q37187946-054B7E47-01E7-45E2-9B06-E68D7DFA0D26

Q37187946-0A67DEB1-F376-4D7B-846F-66DED0218570

Q37187946-0B30ADB9-78E4-4DAD-8066-B248623928D9

Q37187946-0B429D6C-0F1C-4DF8-A9FE-7FF2AEC42408

Q37187946-0C27988B-6178-4E11-9ABB-416FA929877B

Q37187946-0CC15B10-2AF6-4664-8B03-89C4C8CC39BB

Q37187946-10ED0250-FD72-4CBD-A37D-A6C76E117093

Q37187946-113B264A-0EA4-4F59-8FE1-59990A1F6C5F

P304

Q37187946-AF6BDA3C-F725-4B1C-A081-44D56976DE90

P31

Q37187946-027BCFBF-4994-4132-8656-3FCD76E3FB2A

P356

Q37187946-B3D1474F-9F4C-4D95-85E1-0F2D7D7E547F

P433

Q37187946-ADF5D450-8B10-47D2-AABA-A06533E4BD98

P478

Q37187946-87529757-A3D2-4542-A368-6BB06ECE555A

P50

Q37187946-02BD51C1-77A8-4805-8422-D88331624D3A

Q37187946-36EA28D2-73B9-48C9-8AB0-B3DC28E5A028

Q37187946-38380EBF-8FD2-4B4D-A86D-7DE0BD1D463F

Q37187946-5B744B05-4850-49B3-9860-0B820829C7CA

Q37187946-A1072B4E-4610-45F7-8838-46C00CBCCA58

Q37187946-E3C3F8A7-26BF-4FC8-930D-4BFBFBBEBD6F

P577

Q37187946-37FEF6FE-B1B2-49ED-9EC7-DBF3E937D2D3

P5875

Q37187946-654EBE29-863E-40C6-813B-20CE322688D0

P698

Q37187946-EC17B3E6-D4A5-4A63-A0C0-6151D191F5AB

P932

Q37187946-992BE3BA-0429-4C65-8FB7-04C838590529

P356

J.CLINBIOCHEM.2012.12.019

P1433

Clinical Biochemistry

P1476

Rapid development of sensitive ...... eins in human plasma and serum

@en

P2093

Alejandra Garces

http://www.w3.org/2001/XMLSchema#string

Amol Prakash

http://www.w3.org/2001/XMLSchema#string

Bruno Darbouret

http://www.w3.org/2001/XMLSchema#string

Bryan Krastins

http://www.w3.org/2001/XMLSchema#string

Caje Moniz

http://www.w3.org/2001/XMLSchema#string

David A Sarracino

http://www.w3.org/2001/XMLSchema#string

Dobrin Nedelkov

http://www.w3.org/2001/XMLSchema#string

Eric E Niederkofler

http://www.w3.org/2001/XMLSchema#string

Gouri Vadali

http://www.w3.org/2001/XMLSchema#string

Gregory Byram

http://www.w3.org/2001/XMLSchema#string

P2860

SISCAPA peptide enrichment on magnetic beads using an in-line bead trap device.

Mass spectrometric immunoassay.

Serum protein profiling by solid phase extraction and mass spectrometry: a future diagnostics tool?

Selected reaction monitoring-mass spectrometric immunoassay responsive to parathyroid hormone and related variants.

Mass spectrometry-based protein biomarker discovery: solving the remaining challenges to reach the promise of clinical benefit.

Intrapersonal and populational heterogeneity of the chemokine RANTES

C-peptide microheterogeneity in type 2 diabetes populations.

Examining serum amyloid P component microheterogeneity using capillary isoelectric focusing and MALDI-MS

Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma.

Building multidimensional biomarker views of type 2 diabetes on the basis of protein microheterogeneity

P304

399-410

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CLINBIOCHEM.2012.12.019

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

46

http://www.w3.org/2001/XMLSchema#string

P50

Benoit Coulombe

Vathany Kulasingam

P577

2013-01-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

234122233

http://www.w3.org/2001/XMLSchema#string

P698

23313081

http://www.w3.org/2001/XMLSchema#string

P932

3779129

http://www.w3.org/2001/XMLSchema#string